CRISPR Therapeutics AG (CRSP)
54.25
-1.45
(-2.60%)
USD |
NASDAQ |
Sep 25, 16:00
54.26
+0.01
(+0.02%)
After-Hours: 19:59
CRISPR Therapeutics Research and Development Expense (Annual) : 265.33M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 265.33M |
| December 31, 2024 | 301.39M |
| December 31, 2023 | 367.50M |
| December 31, 2022 | 437.47M |
| December 31, 2021 | 420.68M |
| December 31, 2020 | 257.76M |
| Date | Value |
|---|---|
| December 31, 2019 | 174.64M |
| December 31, 2018 | 113.77M |
| December 31, 2017 | 69.80M |
| December 31, 2016 | 42.24M |
| December 31, 2015 | 12.57M |
| December 31, 2014 | 1.513M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Basilea Pharmaceutica AG | 127.51M |
| Santhera Pharmaceuticals Holding AG | 26.75M |
| BeOne Medicines Ltd. | 2.079B |
| AC Immune SA | 67.96M |